|Bid||161.54 x 100|
|Ask||161.61 x 400|
|Day's Range||162.10 - 163.98|
|52 Week Range||158.88 - 209.22|
|PE Ratio (TTM)||166.96|
|Dividend & Yield||0.91 (0.55%)|
|1y Target Est||N/A|
The chief executive of Shire has questioned investors' valuation of his company, arguing the potential of a number of promising drugs has yet to be factored into its share price. Flemming Ornskov also ...
The Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire
Here is a look at 5 pharma and biotech stocks including Merck (MRK) that are expected to post a positive earnings surprise in Q2.